ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2020; 11(7):1839-1845. doi:10.7150/jca.36929 This issue Cite
Research Paper
A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study
1. Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Institute of Prevention and Treatment of Cancer of Heilongjiang Province, Harbin Heilongjiang 150081, China.
2. Department of Phase I Clinical Trials, Harbin Medical University Cancer Hospital.
Citation:
Guo Y, Zheng T, Zhang C, Zhang Y. A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study. J Cancer 2020; 11(7):1839-1845. doi:10.7150/jca.36929. https://www.jcancer.org/v11p1839.htm
Other stylesAbstract
Objectives: To compare the 2-year overall survival (OS) rate and safety between patients using S-1 and capecitabine in the first-treatment of metastatic colorectal cancer in the real clinical setting.
Methods: In this retrospective cohort study, patients satisfying the following criteria were identified from 10 centers in China. The 2-year OS rate and safety were assessed. The propensity score matching (PSM) was used to control basic characteristics of the two groups to balance the processing bias and confoundings.
Results: A total of 1367 patients were identified, 824 patients accepted capecitabine and 546 patients accepted S-1. After PSM, 533 eligible patients were included in each group without statistical significance in age, sex, BMI, KPS score and comorbidities. The 2-year OS rate between two groups was without significant statistical difference (61.9% vs. 62.9%, p=0.4295). The subgroup analysis showed that the 2-year OS rate had no significant difference between men and women, younger and older than 60 years old, different metastatic sites, different chemotherapy courses between S-1 and capecitabine groups. The hematological adverse events were all without statistical difference between two groups, but the incidence of diarrhea (16.4% vs. 23.6%, p=0.0018) and hand-foot syndrome (28.7% vs. 46.7%, p<0.001) in S-1 group were lower than those in the capecitabine group.
Conclusions: Compared to capecitabine, S-1 had a similar 2-year OS rate but had a lower incidence of adverse events in the real clinical setting. So, S-1 could be a good choice in the first-treatment of patients with metastatic colorectal cancer in China.
Keywords: S-1, capecitabine, real-world, metastatic colorectal cancer, first-line treatment
Citation styles
APA
Guo, Y., Zheng, T., Zhang, C., Zhang, Y. (2020). A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study. Journal of Cancer, 11(7), 1839-1845. https://doi.org/10.7150/jca.36929.
ACS
Guo, Y.; Zheng, T.; Zhang, C.; Zhang, Y. A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study. J. Cancer 2020, 11 (7), 1839-1845. DOI: 10.7150/jca.36929.
NLM
Guo Y, Zheng T, Zhang C, Zhang Y. A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study. J Cancer 2020; 11(7):1839-1845. doi:10.7150/jca.36929. https://www.jcancer.org/v11p1839.htm
CSE
Guo Y, Zheng T, Zhang C, Zhang Y. 2020. A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study. J Cancer. 11(7):1839-1845.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.